论文部分内容阅读
目的探讨阿德福韦酯治疗乙肝肝硬化患者的疗效。方法回顾分析2008年1月至2009年12月我院门诊和住院治疗的80例乙肝肝硬化患者的临床资料。结果 2组治疗后HBV DNA及HBeAg阴转率的比较,治疗组中HBeAg/HBeAb的血清学转换5例(13%),而对照组患者无血清学转换。治疗组HbeAg阴转与对照组比较,差异有统计学意义(χ2=4.0530,P<0.05)。治疗组HB-VDNA阴转与对照组比较,差异有统计学意义(χ2=10.80,P<0.01)。观察过程中未发现阿德福韦的相关不良事件发生。结论阿德福韦酯可显著改善患者的临床症状,降低失代偿期肝硬化的发展速度。
Objective To investigate the efficacy of adefovir dipivoxil in the treatment of patients with hepatitis B cirrhosis. Methods The clinical data of 80 patients with hepatitis B cirrhosis from January 2008 to December 2009 in our outpatient department and inpatient hospital were retrospectively analyzed. Results The seroconversion rate of HBeAg / HBeAb in the treatment group was 5 (13%) in the treatment group compared with the negative rate of HBeAg in the two groups after treatment, while the control group had no seroconversion. HbeAg negative conversion in the treatment group compared with the control group, the difference was statistically significant (χ2 = 4.0530, P <0.05). HB-VDNA negative in the treatment group compared with the control group, the difference was statistically significant (χ2 = 10.80, P <0.01). No adefovir-related adverse events were observed during the observation. Conclusion Adefovir dipivoxil can significantly improve the clinical symptoms and reduce the development of decompensated cirrhosis.